Skip to main content

Table 1 Demographic characteristics, outcomes and antibiotics used

From: Proceedings of Réanimation 2020, the French Intensive Care Society International Congress

 20142015p
N patients10091067 
N patients with ICU stay > 48 h767 (76.0%)826 (77.4%)0.45
Age (years)55.5 (19.9%)54.7 (19.6%)0.38
SAPS II mean ± SD42 ± 2440 ± 250.01
All patient’s ICU length of stay > 48 hn = 767n = 826 
SAPS II mean ± SD42 ± 2140 ± 210.08
Sepsis (community or acquired)374 (48.8%)320 (38.7%) < 0.0001
Catecholamines administrated in septic patients170 (22.2%)151 (18.3%)0.06
Primary outcome   
 ICU-acquired ESBL-E145 (18.9%)92 (11.1%) < 0.0001
Secondary outcomes   
 ESBL-E infections60 (7.8%)37 (4.5%)0.005
 All-cause ICU mortality215 (28.0%)184 (22.3%)0.01
 All-cause hospital mortality256 (33.4%)226 (27.4%)0.01
 ICU length of stay, days median ± IQR6 [4–12]5 [4–10]0.02
 Patients who did not receive antibiotic therapy332 (43.3%)440 (53.5%) < 0.0001
 Number of patients receiving antibioticsn = 435n = 386 < 0.0001
Antibiotics administrated   
 Amoxicillin29 (6.7%)67 (17.6%)< 0.0001
 Amoxicillin/ clavulanic acid122 (88.0%)69 (17.9%)< 0.0001
 Piperacillin/tazobactam169 (38.9%)18 (4.7%)< 0.0001
 Cefotaxime/Ceftriaxone (C3G)196 (45.1%)162 (42%)0.37
 Cefoxitin (cephamycin)6 (1.4%)34 (8.8%)< 0.0001
 Ceftazidime19 (4.4%)40 (10.4%)< 0.0001
 Cefepim7 (1.6%)18 (4.3%)0.01
 Carbapenem54 (12.4%)14 (4.7%)< 0.0001
Antibiotics targeting anaerobic pathogens*379 (87.1%)171 (37.5%)< 0.0001